• Explore /
  • Poster
  • / Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).

Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).

Abstract Poster

Authors

null

Rana R. McKay

Dana-Farber Cancer Institute, Boston, MA

Rana R. McKay , Wanling Xie , Rosina Lis , Huihui Ye , Zhenwei Zhang , Quoc-Dien Trinh , Steven Lee Chang , Lauren Christine Harshman , Ashley Ross , Kenneth J. Pienta , Daniel W. Lin , William J Ellis , Robert B. Montgomery , Peter Chang , Andrew Wagner , Glenn Bubley , Adam S. Kibel , Mary-Ellen Taplin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Localized Disease

Clinical Trial Registration Number

NCT02268175

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 79)

DOI

10.1200/JCO.2018.36.6_suppl.79

Abstract #

79

Poster Bd #

D21

Abstract Disclosures

Similar Posters

First Author: Yao Zhu

First Author: Rana R. McKay

First Author: Karan Jatwani

First Author: Junlong Zhuang